Potassium-Sparing Diuretics
Mineralocorticoid-Receptor Antagonists & Epithelial-Na⁺-Channel Blockers — Collecting-Duct Pharmacology, Combination Rationale & Hyperkalaemia Risk
Past RGUHS + MPMSU + MUHS · 7
MUHSSummer '22
MPMSUJul '20
RGUHSNov '17
MPMSU2013
RGUHSMay '09
RGUHSMay '09
RGUHSOct '08
Potassium-Sparing Diuretics
1. Definition, scope & place in the diuretic family
- Potassium-sparing diuretics are agents that act on the late distal tubule (late DCT) and collecting duct (CD) to produce a mild natriuresis while conserving K+ (and H+) — the opposite of the kaliuresis caused by all more proximally acting diuretics (G&G 14e Ch.29; KDT 8e Ch.42, pp.634–6).
- Two mechanistically distinct sub-classes are pooled under this label because they share the net urinary-electrolyte signature (↑Na+, ↓K+, ↑Cl-, slight ↑HCO3-, urine mildly alkalinised) (KDT 8e Ch.42, p.636; G&G 14e Ch.29 Table 29-6/29-7):
- (a) Antagonists of the mineralocorticoid receptor (MR) — "aldosterone antagonists": spironolactone, eplerenone, finerenone (and, outside the U.S./India, canrenone and potassium canrenoate).
- (b) Inhibitors of the renal epithelial Na+ channel (ENaC) — "Na+ channel blockers": amiloride, triamterene.
- They are low-efficacy (weak) diuretics: maximal fractional Na+ excretion ≈ 2–3 % of the filtered load, because >90 % of filtered Na+ is already reabsorbed upstream of their site of action (KDT 8e Ch.42, p.624 & Table 42.2, p.637; G&G 14e Ch.29).
- Consequently they are rarely used as sole agents; their principal roles are (i) to offset the K+ (and Mg2+) loss of loop/thiazide diuretics, (ii) to add a small natriuretic/antihypertensive increment, and (iii) MR antagonists specifically — to deliver disease-modifying benefit in heart failure, primary aldosteronism, cirrhotic ascites and diabetic CKD (G&G 14e Ch.29; KDT 8e Ch.42, pp.634–6).
- Historical note: spironolactone (aldosterone antagonist) and the ENaC blockers triamterene/amiloride were developed in parallel with the thiazides and loop diuretics in the late 1950s–1960s, expressly to counter diuretic-induced hypokalaemia (KDT 8e Ch.42, p.625).
Comparative urinary-electrolyte signature and efficacy (KDT 8e Ch.42 Table 42.2, p.637)
- Spironolactone — Na+ ↑, K+ ↓, Cl- ↑, HCO3- –/↑; max ~3 % filtered Na+ excreted; efficacy Low.
- Amiloride — Na+ ↑, K+ ↓, Cl- ↑, HCO3- –/↑; max ~3 % filtered Na+ excreted; efficacy Low.
- (Contrast: furosemide 25 % / High; thiazide 8 % / Intermediate; acetazolamide 5 % / Mild.)
Continue reading
Potassium Sparing Diuretics
PharmaNotes Pro · Comprehensive
Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.